# US 8,465,914 B2 · Method and compositions involving microRNA > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,465,914 B2 - Document ID: US8465914B2 - Status: Granted - Kind: B2 - Application number: 13/540,413 - Filed: 2012-07-02 - Published: 2013-01-17 - Granted: 2013-06-18 - Earliest claimed: 2004-05-28 - Assignees: Asuragen, Inc. - Applicants: David Brown; Rick Conrad; Eric Devroe; Marianna Goldrick; Kerri Keiger; Emmanuel Labourier; Ivonne Moon; Patricia Powers; Jeffrey Shelton; Jaclyn Shingara - Inventors: David Brown; Rick Conrad; Eric Devroe; Marianna Goldrick; Kerri Keiger; Emmanuel Labourier; Ivonne Moon; Patricia Powers; Jeffrey Shelton; Jaclyn Shingara - Web page: https://patentgrep.com/patent/US8465914B2 ## CPC - A61P 35/00: Antineoplastic agents - C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence) - C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids} - C12P 19/34: Polynucleotides, e.g. nucleic acids, oligoribonucleotides - C12Q 1/6809: Methods for determination or identification of nucleic acids involving differential detection - C12Q 1/6883: for diseases caused by alterations of genetic material - C12N 2310/14: interfering nucleic acids [NA] - C12N 2310/3517: Marker; Tag - C12N 2310/3519: Fusion with another nucleic acid - C12N 2320/10: in screening processes - C12Q 2600/158: Expression markers - C12Q 2600/178: miRNA, siRNA or ncRNA - Y02A 90/10: Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)} - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract The present invention concerns methods and compositions for isolating, enriching, and/or labeling miRNA molecules and for preparing and using arrays or other detection techniques for miRNA analysis. Moreover, the present invention concerns methods and compositions for generating miRNA profiles and employing such profiles for therapeutic, diagnostic, and prognostic applications. ## Claims ### Claim 1 A method for evaluating a thyroid sample in a patient comprising: a) measuring the expression level of miR-21 in the sample; b) comparing the expression level to the expression level of the same miRNAs in a noncancerous thyroid sample; and, c) identifying the patient as having a marker for thyroid cancer if the sample is determined to have increased expression of miR-21. ### Claim 2 (depends on 1) The method of claim 1, wherein the sample is determined to have increased expression of miR-21. ### Claim 3 (depends on 1) The method of claim 1, wherein the sample is determined not to have increased expression of miR-21 and further comprising identifying the patient as not having increased expression of miR-21. ### Claim 4 (depends on 1) The method of claim 1, further comprising obtaining the sample from the patient. ### Claim 5 (depends on 1) The method of claim 1, wherein the noncancerous sample is a benign thyroid sample. ### Claim 6 (depends on 1) The method of claim 1, further comprising measuring the expression level of miR-222. ### Claim 7 (depends on 6) The method of claim 6, wherein the sample is determined to have increased expression of miR-222. ### Claim 8 (depends on 1) The method of claim 1, further comprising measuring the expression level of one or more of the following miRNAs: miR-10a, miR-15A, miR-22, miR-24, miR-29b, miR-30a, miR-30A-as, miR-31, miR-125, miR-126, miR-135A, miR-138, miR-145, miR-152, miR-183, miR-197, miR-199a, miR-199A-as, miR-200b, miR-203, miR-221, miR-223, miR-224, or miR-331. ### Claim 9 (depends on 7) The method of claim 7, further comprising measuring the expression level of one or more of the following miRNAs: miR-10a, miR-15A, miR-22, miR-24, miR-29b, miR-30a, miR-30A-as, miR-31, miR-125, miR-126, miR-135A, miR-138, miR-145, miR-152, miR-183, miR-197, miR-199a, miR-199A-as, miR-200b, miR-203, miR-221, miR-223, miR-224, or miR-331. ### Claim 10 A method for evaluating a thyroid sample in a patient comprising: a) measuring an increased expression level of miR-21 in the sample compared to the expression level of miR-21 in a noncancerous thyroid sample; and, b) identifying the patient as having a marker for thyroid cancer. ### Claim 11 (depends on 10) The method of claim 10, further comprising measuring the expression level of miR-222 in the sample. ### Claim 12 (depends on 11) The method of claim 11, wherein the sample is determined to have increased expression of miR-222. ### Claim 13 (depends on 10) The method of claim 10, wherein the noncancerous thyroid sample comprises benign cells. ### Claim 14 (depends on 10) The method of claim 10, further comprising obtaining the sample from the thyroid of the patient. ### Claim 15 (depends on 10) The method of claim 10, further comprising measuring the expression level of one or more of the following miRNAs: miR-10a, miR-15A, miR-22, miR-24, miR-29b, miR-30a, miR-30A-as, miR-31, miR-125, miR-126, miR-135A, miR-138, miR-145, miR-152, miR-183, miR-197, miR-199a, miR-199A-as, miR-200b, miR-203, miR-221, miR-223, miR-224, or miR-331. ### Claim 16 (depends on 11) The method of claim 11, further comprising measuring the expression level of one or more of the following miRNAs: miR-10a, miR-15A, miR-22, miR-24, miR-29b, miR-30a, miR-30A-as, miR-31, miR-125, miR-126, miR-135A, miR-138, miR-145, miR-152, miR-183, miR-197, miR-199a, miR-199A-as, miR-200b, miR-203, miR-221, miR-223, miR-224, or miR-331.